NCT06035250 AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
| NCT ID | NCT06035250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Sciences |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-09-10 |
| Primary Completion | 2024-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-09-10 with a primary completion date of 2024-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older; * Pathologically diagnosed with advanced gastric cancer in accordance with the American AJCC's TNM staging standards; * Have not undergone any systematic anti-cancer treatments before neoadjuvant chemotherapy and have not had surgery for local progression or distant metastasis; * Received standard neoadjuvant chemotherapy as recommended by the clinical guidelines, and have documented treatment details; * CT imaging and biopsy pathology images strictly taken within one month prior to starting neoadjuvant treatment; * Patients possess comprehensive preoperative clinical information and post-operative TRG grading. Exclusion Criteria: * Patients whose CT or pathology images are unclear, making lesion assessment infeasible; * Patients diagnosed with other concurrent tumors.
Contact & Investigator
Yali Zang, Ph.D.
STUDY DIRECTOR
Institute of Automation, Chinese Academy of Sciences
Frequently Asked Questions
Who can join the NCT06035250 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06035250 currently recruiting?
Yes, NCT06035250 is actively recruiting participants. Contact the research team at di.dong@ia.ac.cn for enrollment information.
Where is the NCT06035250 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Beijing, China and 11 additional locations.
Who is sponsoring the NCT06035250 clinical trial?
NCT06035250 is sponsored by Chinese Academy of Sciences. The principal investigator is Yali Zang, Ph.D. at Institute of Automation, Chinese Academy of Sciences. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.